Daiichi Sankyo Co., Ltd.
π―π΅Japan
- Country
- π―π΅Japan
- Ownership
- Public
- Established
- 2005-09-28
- Employees
- 18.7K
- Market Cap
- -
Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT02222350
- Locations
- π―π΅
Heishinkai Medical Group Incorporated OCROM Clinic, Kasuga, Osaka, Japan
Open Label Study of DS-5573a
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT02192567
- Locations
- π―π΅
National Cancer Center Hospital, Tokyo, Japan
Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT02004717
- Locations
- π―π΅
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
π―π΅Osaka University Hospital, Suita, Osaka, Japan
Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT01857622
- Locations
- π―π΅
Tokyo Women's Medical University Hospital, Tokyo, Japan
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT01857583
- Locations
- π―π΅
Toyooka Chuo Hospital, Asahikawa, Hokkaido Prefecture, Japan
Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-05
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT01504412
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 264
- Registration Number
- NCT01203098
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 523
- Registration Number
- NCT01203072
CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 15
- Registration Number
- NCT01199068
- Locations
- π°π·
Asan Medical Center, Seoul, Songpa-Gu, Korea, Republic of
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT01199055
- Locations
- π°π·
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
Β© Copyright 2024. All Rights Reserved by MedPath